EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

Inhibition of Colorectal Cancer by Perillaldehyde Through Targeting SRD5A1 to Induce Autophagy via the PI3K/AKT Pathway

Zhuyun Leng, Yiqian Zhang, Mingming Guo, Yan Chen, Zhiyong Wang

Drug Design, Development and Therapy · 2025-07 · Volume 19 · 6399-6412

DOI: 10.2147/dddt.s525006 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025-07. Verfasst von Zhuyun Leng und 4 weiteren Autor:innen. Beteiligte Einrichtung: Endoscopy Center, Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, People's Republic …. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Autophagy, Proto-Oncogene Proteins c-akt, Membrane Proteins. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Colorectal cancer (CRC) is the third most common cancer globally, with treatment challenges persisting. Perillaldehyde (PAH), a major active monomer extracted from Perilla, has shown potential against CRC, though its mechanisms remain unclear. This study aims to assess the therapeutic potential of PAH against CRC and to clarify its mechanisms of action, providing a rationale for PAH as a promising candidate for anti-CRC therapy.

Methods

In vitro, we used CCK-8, colony formation, EdU assays, flow cytometry, and Western blotting to assess the effects of PAH on CRC cell proliferation and apoptosis. In vivo, a subcutaneous xenograft mouse model was established to evaluate the anti-CRC efficacy of PAH. Transcriptomic analysis was performed to identify possible mechanisms, particularly related to autophagy, and validated through TEM, immunofluorescence, Western blotting, and inhibitor assays. SRD5A1 was predicted as a potential target using Swiss Target Prediction and confirmed by molecular docking, molecular dynamics simulation, and CETSA. Bioinformatics analysis further assessed the clinical relevance and mechanism of SRD5A1, which was validated using a selective inhibitor.

Results

PAH demonstrated inhibitory effects on CRC in both experimental models. RNA-seq and experimental validation suggest that PAH may inhibit CRC by modulating the PI3K/AKT pathway to induce autophagy. Bioinformatics analysis indicates that SRD5A1 could be a potential target of PAH, with PAH treatment reducing SRD5A1 levels and enhancing autophagic activity through PI3K/AKT suppression.

Conclusion

PAH appears to inhibit CRC by targeting SRD5A1, thereby promoting autophagy through the PI3K/AKT pathway. This offers new perspectives for both the diagnosis and treatment of CRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsAutophagyProto-Oncogene Proteins c-aktMembrane ProteinsAntineoplastic AgentsHumansPhosphatidylinositol 3-KinasesAnimalsMiceCell ProliferationDrug Screening Assays, AntitumorMolecular Docking SimulationDose-Response Relationship, DrugApoptosisMolecular StructureStructure-Activity RelationshipNeoplasms, ExperimentalMice, NudeMice, Inbred BALB CTumor Cells, CulturedSignal Transduction

Stichwörter der Autor:innen

PI3K/AKT pathwaySRD5A1autophagycolorectal cancerperillaldehyde

Substanzen

Proto-Oncogene Proteins c-aktPhosphatidylinositol 3-KinasesMembrane ProteinsAntineoplastic Agents

Autor:innen und Institutionen

  • Endoscopy Center, Department of Gastroenterology, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai, 200120, People's Republic of China.
  • Xiangan Hospital Xiamen University, China, School of Medicine, Xiamen University, Xiamen, 361100, People's Republic of China.
  • Naval Medical University, Shanghai, 200433, People's Republic of China.
  • Department of Pharmacy, Xiamen Susong Hospital, Xiamen, 361100, People's Republic of China.

Zitieren

APA

Leng, Z., Zhang, Y., Guo, M., Chen, Y., & Wang, Z. (2025). Inhibition of Colorectal Cancer by Perillaldehyde Through Targeting SRD5A1 to Induce Autophagy via the PI3K/AKT Pathway. Drug Design, Development and Therapy, Volume 19, 6399-6412. https://doi.org/10.2147/dddt.s525006

Vancouver

Leng Z, Zhang Y, Guo M, Chen Y, Wang Z. Inhibition of Colorectal Cancer by Perillaldehyde Through Targeting SRD5A1 to Induce Autophagy via the PI3K/AKT Pathway. Drug Design, Development and Therapy. 2025;Volume 19:6399-6412. doi:10.2147/dddt.s525006

BibTeX
@article{Leng2025,
  author = {Leng, Zhuyun and Zhang, Yiqian and Guo, Mingming and Chen, Yan and Wang, Zhiyong},
  title = {Inhibition of Colorectal Cancer by Perillaldehyde Through Targeting SRD5A1 to Induce Autophagy via the PI3K/AKT Pathway},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  volume = {Volume 19},
  pages = {6399--6412},
  doi = {10.2147/dddt.s525006}
}
Kostenlos starten →